Jiangsu Genscend Biopharmaceutical Co., Ltd

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Recruiting	Phase 1	2026-05-20		NCT07411755
A Phase III Study of GS101 Injection to Dupixent®	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Not yet recruiting	Phase 3	2026-02-04		NCT07386743

Clinical trials